| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 660,500 | 701,300 | 710,300 | 651,300 | 697,000 |
| Sales Growth | -5.82% | -1.27% | +9.06% | -6.56% | +3.27% |
| Net Income | -32,500 | -15,900 | -374,900 | -562,900 | -61,200 |
| Net Income Growth | -104.40% | +95.76% | +33.40% | -819.77% | -119.35% |
Fortrea Holdings Inc (FTRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fortrea Holdings Inc. is a provider of clinical development and patient access solutions to the life sciences industry. It provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea Holdings Inc. is based in DURHAM, N.C.
Fiscal Year End Date: 12/31